Abstract
Protein tyrosine phosphatases (PTPs) constitute a large family of enzymes that can exert both positive and negative effects on signaling pathways. They play dominant roles in setting the levels of intracellular phosphorylation downstream of many receptors including receptor tyrosine kinases and G protein-coupled receptors. As observed with kinases, deregulation of PTP activity can also contribute to cancer. This review will examine a broad array of PTP family members that positively affect oncogenesis in human cancer tissues. We will describe the PTP family, their biological significance in oncology, and how recent progress is being made to more effectively target specific PTPs. Finally, we will discuss the therapeutic implications of targeting these oncogenic PTPs in cancer.
Keywords: Cancer, Inhibitors, dual-specificity phosphatases (DSPs), Oncogene, Protein tyrosine phosphatases, Phosphorylation, Tumor suppressor, G protein-coupled receptors (GPCRs), Amplification, Gynecological Cancers
Anti-Cancer Agents in Medicinal Chemistry
Title: Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Volume: 12 Issue: 1
Author(s): Serge Hardy, Sofi G. Julien and Michel L. Tremblay
Affiliation:
Keywords: Cancer, Inhibitors, dual-specificity phosphatases (DSPs), Oncogene, Protein tyrosine phosphatases, Phosphorylation, Tumor suppressor, G protein-coupled receptors (GPCRs), Amplification, Gynecological Cancers
Abstract: Protein tyrosine phosphatases (PTPs) constitute a large family of enzymes that can exert both positive and negative effects on signaling pathways. They play dominant roles in setting the levels of intracellular phosphorylation downstream of many receptors including receptor tyrosine kinases and G protein-coupled receptors. As observed with kinases, deregulation of PTP activity can also contribute to cancer. This review will examine a broad array of PTP family members that positively affect oncogenesis in human cancer tissues. We will describe the PTP family, their biological significance in oncology, and how recent progress is being made to more effectively target specific PTPs. Finally, we will discuss the therapeutic implications of targeting these oncogenic PTPs in cancer.
Export Options
About this article
Cite this article as:
Hardy Serge, G. Julien Sofi and L. Tremblay Michel, Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (1) . https://dx.doi.org/10.2174/187152012798764741
DOI https://dx.doi.org/10.2174/187152012798764741 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry Cigarette Smoking, Metabolic Activation and Carcinogenesis
Current Drug Metabolism The Association of Sleep Disorders, Obesity and Sleep-Related Hypoxia with Cancer
Current Genomics The Urokinase Receptor as a Potential Target in Cancer Therapy
Current Pharmaceutical Design Regulation and Function of DNA and Histone Methylations
Current Pharmaceutical Design It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry MicroRNAs Regulate the Epithelial to Mesenchymal Transition (EMT) in Cancer Progression
MicroRNA Cancer and Phase II Drug-Metabolizing Enzymes
Current Drug Metabolism Recent Patents of DNA Methylation Biomarkers in Gastrointestinal Oncology
Recent Patents on DNA & Gene Sequences Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Current Drug Targets Targeting the Hippo Pathway for Anti-cancer Therapies
Current Medicinal Chemistry Synthesis and Biological Activity of Chiral Dihydropyrazole: Potential Lead for Drug Design
Mini-Reviews in Medicinal Chemistry CD133+ Glioblastoma Stem-Like Cells Induce Vascular Mimicry in Vivo
Current Neurovascular Research Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology COX-2 Inhibition in Esophagitis, Barretts Esophagus and Esophageal Cancer
Current Pharmaceutical Design Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Angiogenesis Inhibitors and Radiation in Multimodality Cancer Therapy: Preclinical and Clinical Studies
Current Angiogenesis (Discontinued) Recent Advances in pH-Sensitive Polymeric Nanoparticles for Smart Drug Delivery in Cancer Therapy
Current Drug Targets Synthesis of Pyridine and Spiropyridine Derivatives Derived from 2-aminoprop- 1-ene-1,1,3-tricarbonitrile Together with their c-Met Kinase and Antiproliferative Evaluations
Anti-Cancer Agents in Medicinal Chemistry